Shire partners with Rani Therapeutics for haemophilia therapy

MaxCyte and NIH to develop therapies for sickle cell disease
Credit: Romaset

A new collaboration will see Shire research Rani Therapeutics’ Rani Pill technology for the oral delivery of factor therapy for patients with haemophilia A.

The collaboration agreement grants Shire an exclusive option to negotiate a license to develop and commercialise the technology for delivery of FVIII therapy following completion of feasibility studies.

As part of the collaboration, Shire has also made an undisclosed equity investment into Rani Therapeutics.

Founded in 2012 and spun out of InCube Labs, Rani Therapeutics has developed a technology platform to convert injectable drugs, such as TNF-alpha Inhibitors, interleukin antibodies and basal insulin, among others, into pills.

It has developed a novel approach for the oral delivery of large molecules – including peptides, proteins, and antibodies – using the Rani Pill, a capsule that delivers an intestinal injection without exposing medication to digestive enzymes.

Once the capsule is consumed, it stays protected until it enters the small intestine and delivers medication into the intestinal wall. Since the intestines do not have sharp pain receptors, the intestinal delivery is expected to be pain free.

Mir Imran, Chairman and CEO, Rani Therapeutics, said: “With this technology, though early in development in haemophilia, we hope to improve compliance, quality of life and outcomes for patients with haemophilia by offering a painless and more convenient oral delivery.”